Goldman Sachs Starts Bio-Rad Labs (BIO) at Buy

Goldman Sachs analyst Patrick Donnelly initiates coverage on Bio-Rad Labs (NYSE: BIO) with a Buy rating and a price target of $350.00.

The analyst believes the company is in the early stages of a margin expansion story following a lengthy peer of under-earning against peers while stable revenue growth and an improving capital allocation story-line will build on the margins to generate well-above peers EPS growth.

For an analyst ratings summary and ratings history on Bio-Rad Labs click here. For more ratings news on Bio-Rad Labs click here.

Shares of Bio-Rad Labs closed at $289.31 yesterday.

You May Also Be Interested In

• Cantor Fitzgerald Starts Milestone Pharmaceuticals (MIST) at Overweight
• Benchmark Reiterates Buy Rating on Strive Enterprises, Inc. (ASST), Highlights Differentiated Risk Management
• Nutanix (NTNX) PT Raised to $80 at Oppenheimer Into EPS